• Explore /
  • Poster
  • / Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).

Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).

Abstract Poster

Authors

null

Giuseppe Procopio

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Giuseppe Procopio , Alessia Mennitto , Massimo Di Maio , Emma Zattarin , Marco Maruzzo , Ugo De Giorgi , Daniele Santini , Sebastiano Buti , Chiara Casadei , Mariella Soraru' , Giuseppe Di Lorenzo , Carlo Messina , Claudia Mucciarini , Giandomenico Roviello , Consuelo Buttigliero , Marco Stellato , Pierangela Sepe , Sandro Pignata , Filippo G. De Braud , Elena Verzoni

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 320)

DOI

10.1200/JCO.2021.39.6_suppl.320

Abstract #

320

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Esmail Mutahar Al-Ezzi

First Author: Gabriel Tremblay

First Author: Andrew Johns

First Author: Igor Stukalin